Compare

Imunon, Inc. vs PRF Technologies Ltd. vs Propanc Biopharma, Inc. vs PMGC Holdings Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearImunon, Inc.
IMNN
PRF Technologies Ltd.
PRFX
Propanc Biopharma, Inc.
PPCB
PMGC Holdings Inc.
ELAB
Year ended2025-12-312025-12-312026-06-302025-12-31
Revenuen/a$17.0Kn/a$590.1K
Revenue growth (YoY)n/an/an/an/a
Gross marginn/a-311.8% (computed)n/a31.4%
Operating marginn/an/mn/an/a
Net marginn/an/mn/an/m
Net income-$14.50M-$5.02M-$18.86M-$7.75M
EPS (Diluted)-$6.83-$7.47-$17.62n/a
Operating cash flow-$13.90M-$3.96M-$5.68M-$5.93M
Free cash flow-$14.18M-$3.96M-$5.69M-$6.38M
Cash & equivalents$8.78M$3.12Mn/an/a
Total assets$12.29M$12.00M$12.78M$12.87M
Total liabilities$5.23M$2.71M$3.38M$5.03M
Shareholders' equity$7.06M$8.54M$9.40M$7.84M
Return on year-end equity-205.3%-58.8%-200.6%-98.9%
Shares outstanding3.42M830.6K3.31M80.7K

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearImunon, Inc.PRF Technologies Ltd.Propanc Biopharma, Inc.PMGC Holdings Inc.
Latest$500.0K
Ended 2022-12-31
$17.0K
Ended 2025-12-31
n/a$590.1K
Ended 2025-12-31
1 year earlier$500.0K
Ended 2021-12-31
$0
Ended 2024-12-31
n/an/a
2 years earlier$500.0K
Ended 2020-12-31
$0
Ended 2023-12-31
n/a$1.71M
Ended 2023-12-31
3 years earlier$500.0K
Ended 2019-12-31
n/an/a$766.3K
Ended 2022-12-31
4 years earlier$500.0K
Ended 2018-12-31
n/an/an/a